# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Northland Capital Markets analyst Carl Byrnes downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perf...
https://www.vabio.org/event/use-of-tempol-as-an-antiviral-therapeutic-against-covid-19/
-SEC Filing
Upgrades
JMP Securities analyst Jason Butler downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Market Outperform to Market Perform.
Piper Sandler analyst David Amsellem downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Overweight to Neutral and raises t...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Buy to Neutral and l...
Gainers